Stifel Nicolaus Has Lowered Expectations for Cipher Pharmaceuticals (TSE:CPH) Stock Price

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price objective reduced by Stifel Nicolaus from C$19.00 to C$17.00 in a research note issued to investors on Monday morning,BayStreet.CA reports.

CPH has been the subject of a number of other research reports. Leede Financial lowered Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th. Stifel Canada raised Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.

Cipher Pharmaceuticals Price Performance

Shares of TSE CPH opened at C$13.80 on Monday. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. Cipher Pharmaceuticals has a fifty-two week low of C$5.31 and a fifty-two week high of C$19.69. The business has a 50 day moving average price of C$15.75 and a two-hundred day moving average price of C$12.37. The firm has a market cap of C$353.14 million, a PE ratio of 11.04 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). The company had revenue of C$14.15 million for the quarter, compared to analyst estimates of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Sell-side analysts expect that Cipher Pharmaceuticals will post 1.2907348 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.